Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 17/20 | 0.62 |
| ▸ | BRD2 | P25440 | 1/20 | 0.62 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.62 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22735695 | 0.91 | BRD4 (0.64) | BRD4BRD2BRD3BRDTKMT2A | |
| SCHEMBL22735940 | 0.91 | BRD4 (0.67) | BRD4BRD2BRD3BRDTKMT2A | |
| SCHEMBL22734479 | 0.85 | BRD4 (0.60) | BRD4BRD2BRD3BRDT | |
| SCHEMBL22400721 | 0.85 | BRD4 (0.73) | BRD4BRD2BRD3BRDTKMT2A | |
| SCHEMBL22712636 | 0.80 | BRD4 (0.63) | BRD4BRD2BRD3BRDTPDE4A | |
| SCHEMBL22734591 | 0.80 | BRD4 (0.66) | BRD4BRD2BRD3BRDTKMT2A | |
| SCHEMBL22734660 | 0.79 | BRD4 (0.64) | BRD4BRD2BRD3BRDTPDE4A | |
| SCHEMBL22734585 | 0.79 | BRD4 (0.74) | BRD4BRD2BRD3BRDT | |
| SCHEMBL22735801 | 0.79 | BRD4 (0.73) | BRD4BRD2BRD3BRDTKMT2A | |
| SCHEMBL24247541 | 0.78 | BRD4 (0.59) | BRD4BRD2BRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-11-23 | — | — | US | disclosed |
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377522-A1 | XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 6/4885BRD3 3/4885 |
| US-11180510-B2 | Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 6/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.